Who owns Corvus Pharmaceuticals?
- Ticker: CRVS
- CUSIP Number: 221015100
Tip: Access positions for across all investors
Analyze quarterly positions in Corvus Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Corvus Pharmaceuticals stock
Who bought or sold Corvus Pharmaceuticals this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| OrbiMed Advisors | 6.9M | $12M | 0% | Mar 2024 |
|
| Samlyn Capital | 2.3M | $4.2M | -6% | Mar 2024 |
|
| Vanguard Group | 1.5M | $2.7M | 11% | Mar 2024 |
|
| BlackRock | 523k | $931k | 0% | Mar 2024 |
|
| TowerView | 383k | $681k | -12% | Mar 2024 |
|
| Geode Capital Management | 372k | $662k | 3% | Mar 2024 |
|
| BVF | 361k | $643k | -74% | Mar 2024 |
|
| Morgan Stanley | 275k | $490k | 43% | Mar 2024 |
|
| Bridgeway Capital Management | 224k | $399k | 50% | Mar 2024 |
|
| Two Sigma Advisers | 185k | $330k | -21% | Mar 2024 |
|
| Susquehanna International | 144k | $256k | -28% | Mar 2024 |
|
| Two Sigma Investments | 102k | $182k | -43% | Mar 2024 |
|
| Connor, Clark & Lunn Investment Management | 88k | $157k | 24% | Mar 2024 |
|
| Northern Trust | 65k | $116k | 0% | Mar 2024 |
|
| Jackson Square Capital | 64k | $114k | 0% | Mar 2024 |
|
| Jpmorgan Chase & Co | 53k | $94k | 7680% | Mar 2024 |
|
| Hikari Power | 50k | $89k | 0% | Mar 2024 |
|
| Millennium Management | 23k | $41k | -43% | Mar 2024 |
|
| Citadel Advisors | 22k | $38k | -58% | Mar 2024 |
|
| Commerce Bank N A | 20k | $36k | 0% | Mar 2024 |
|
| American Century Companies | 18k | $33k | -3% | Mar 2024 |
|
| Resources Investment Advisors | 18k | $32k | 100% | Mar 2024 |
|
| Charles Schwab Investment Management | 16k | $28k | 0% | Mar 2024 |
|
| Virtu Financial | 13k | $22k | 100% | Mar 2024 |
|
| Dimensional Fund Advisors | 12k | $21k | 0% | Mar 2024 |
|
| Tower Research Capital | 12k | $21k | -53% | Mar 2024 |
|
| Gillespie Robinson & Grimm | 12k | $20k | 0% | Mar 2024 |
|
| Whittier Trust Co. of Nevada | 11k | $20k | 0% | Mar 2024 |
|
| Fortem Financial Group | 11k | $20k | 100% | Mar 2024 |
|
| Masso Torrence Wealth Management | 10k | $18k | 0% | Mar 2024 |
|
| Simplex Trading | 9.3k | $16k | -81% | Mar 2024 |
|
| UBS Group | 4.7k | $8.3k | -30% | Mar 2024 |
|
| Group One Trading | 4.6k | $8.2k | -83% | Mar 2024 |
|
| Northwest Capital Management | 3.4k | $6.0k | 0% | Mar 2024 |
|
| Qube Research & Technologies | 2.4k | $4.2k | 100% | Mar 2024 |
|
| Advisor Group Holdings | 1.2k | $2.1k | 0% | Mar 2024 |
|
| Rhumbline Advisers | 791.00 | $1.4k | 0% | Mar 2024 |
|
| Wells Fargo & Company | 265.00 | $471.991500 | 2% | Mar 2024 |
|
| ICA Group Wealth Management | 165.00 | $293.997000 | 100% | Mar 2024 |
|
| IFP Advisors | 24.00 | $42.000000 | 0% | Dec 2023 |
|
| Parallel Advisors | 20.00 | $36.000000 | 0% | Mar 2024 |
|
| FMR | 17.00 | $29.999900 | -98% | Mar 2024 |
|
| Barclays | 1.00 | $0 | 0% | Mar 2024 |
|
Who sold out of Corvus Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Jane Street | Dec 2023 | 23k | $41k |
| Bank of New York Mellon | Dec 2023 | 21k | $37k |
| XTX Topco | Sep 2023 | 19k | $28k |
| Natixis | Sep 2023 | 800.00 | $1.2k |
| Royal Bank of Canada | Dec 2023 | 122.00 | $0 |
| Bank of America Corporation | Dec 2023 | 22.00 | $38.999400 |